Delivra Health Brands (DHB) Q4 2026 earnings summary

Executive summary

• FY2026 was a challenging year, with lower revenue and an Adjusted EBITDA loss amid geopolitical disruption, tariffs, cost pressures, and business changes.

• Core business strength and Canadian and U.S. e-commerce growth supported plans to rebuild sales volumes and profitability in FY2027.

Financial highlights

• Net revenue was $8,629 thousand, down 35.5% from $13,370 thousand in FY2025.

• Gross profit was $3,335 thousand versus $6,778 thousand; gross margin fell to 39% from 51%.

• Expenses excluding non-cash items declined 14% to $5,237 thousand; sales and marketing fell 34% to $1,296 thousand, and G&A decreased 4% to $3,941 thousand.

• Net loss from continuing operations was $2,254 thousand versus $1,190 thousand; loss from operations was $2,058 thousand versus $841 thousand.

• Net cash used in operating activities was $637 thousand versus $754 thousand; inventory write-down was $57 thousand versus a $64 thousand recovery.

Outlook and guidance

• FY2027 priorities include normalizing retail ordering patterns, growing e-commerce, improving LivRelief Infused performance, and advancing product innovation.

• Management aims to rebuild sales volumes and profitability across Dream Water and LivRelief product lines, and expects licensed LivRelief Infused growth to resume in FY2027.

• New products launched in FY2026 are expected to benefit the business in the near to long term.